Skip to main content
internurse.com | The UK's largest nursing archive

Advanced search

J-E. Torra i Bou, T. Segovia Gómez, J. Verdú Soriano, A. Nolasco Bonmatí, J. Rueda López, M. Arboix i Perejamo
Journal of Wound Care, Vol. 14, Iss. 3, 01 Mar 2005, pp 117 - 121

Objective: To compare the effects of Mepentol, a hyperoxygenated fatty acid preparation, with a placebo treatment in preventing the development of pressure ulcers.
Method: The research study consisted of a multicentre double-blind randomised clinical trial. The incidence of pressure ulcers, relative risk (RR), preventable fraction and number necessary to treat (NNT) were calculated. In addition, Kaplan-Meier survival curves, with log-rank test, and Cox’s proportional hazards regression model were used to compare both groups.
Results: A total of 331 patients completed the study: 167 in the control group and 164 in the
study group. Pressure-ulcer incidence during the study was 7.32% in the intervention group versus 17.37% in the placebo group (p0.006). These results show that for each 10 patients treated with Mepentol one pressure ulcer was prevented (NNT = 9.95). Survival curves and the regression model showed a significant statistical difference for both groups (p?0.001). The average cost of Mepentol
during the study was 27.74.
Conclusion: Mepentol is an effective measure for pressure ulcer prevention. It was more effective than a greasy placebo product, and was found to be cost-effective.
Declaration of interest: This study was sponsored by Laboratorios Bama-Geve SA, Barcelona, Spain.

Return to article listing Request Permissions

To view this article


Existing users sign in Personal subscription 24 Hour access Pay per article